196 related articles for article (PubMed ID: 17014006)
1. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.
Weisman MH; Durez P; Hallegua D; Aranda R; Becker JC; Nuamah I; Vratsanos G; Zhou Y; Moreland LW
J Rheumatol; 2006 Nov; 33(11):2162-6. PubMed ID: 17014006
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.
Haggerty HG; Abbott MA; Reilly TP; DeVona DA; Gleason CR; Tay L; Dodge R; Aranda R
J Rheumatol; 2007 Dec; 34(12):2365-73. PubMed ID: 18050376
[TBL] [Abstract][Full Text] [Related]
3. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
Sherrer Y
Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
[TBL] [Abstract][Full Text] [Related]
4. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):276-84. PubMed ID: 19228144
[TBL] [Abstract][Full Text] [Related]
5. Role of abatacept in the management of rheumatoid arthritis.
Nogid A; Pham DQ
Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
[TBL] [Abstract][Full Text] [Related]
6. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
Kremer JM; Dougados M; Emery P; Durez P; Sibilia J; Shergy W; Steinfeld S; Tindall E; Becker JC; Li T; Nuamah IF; Aranda R; Moreland LW
Arthritis Rheum; 2005 Aug; 52(8):2263-71. PubMed ID: 16052582
[TBL] [Abstract][Full Text] [Related]
7. Abatacept mechanism of action: concordance with its clinical profile.
Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S
Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048
[TBL] [Abstract][Full Text] [Related]
8. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis.
Roy A; Mould DR; Wang XF; Tay L; Raymond R; Pfister M
J Clin Pharmacol; 2007 Nov; 47(11):1408-20. PubMed ID: 17962428
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of abatacept in rheumatoid arthritis: a review.
Khraishi M; Russell A; Olszynski WP
Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
[TBL] [Abstract][Full Text] [Related]
11. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.
Reynolds J; Shojania K; Marra CA
Pharmacotherapy; 2007 Dec; 27(12):1693-701. PubMed ID: 18041889
[TBL] [Abstract][Full Text] [Related]
12. T-cell agents in the treatment of rheumatoid arthritis.
Solomon GE
Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545
[TBL] [Abstract][Full Text] [Related]
13. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.
Sibilia J; Westhovens R
Clin Exp Rheumatol; 2007; 25(5 Suppl 46):S46-56. PubMed ID: 17977488
[TBL] [Abstract][Full Text] [Related]
14. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
Massarotti EM
Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
[TBL] [Abstract][Full Text] [Related]
15. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
Scheinfeld N
J Dermatolog Treat; 2006; 17(4):229-34. PubMed ID: 16971318
[TBL] [Abstract][Full Text] [Related]
16. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
Weinblatt M; Schiff M; Goldman A; Kremer J; Luggen M; Li T; Chen D; Becker JC
Ann Rheum Dis; 2007 Feb; 66(2):228-34. PubMed ID: 16935912
[TBL] [Abstract][Full Text] [Related]
17. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
[TBL] [Abstract][Full Text] [Related]
18. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
Weinblatt M; Combe B; Covucci A; Aranda R; Becker JC; Keystone E
Arthritis Rheum; 2006 Sep; 54(9):2807-16. PubMed ID: 16947384
[TBL] [Abstract][Full Text] [Related]
19. Drug Insight: abatacept for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Nat Clin Pract Rheumatol; 2006 Dec; 2(12):654-60. PubMed ID: 17133250
[TBL] [Abstract][Full Text] [Related]
20. Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.
Shergy WJ
Semin Arthritis Rheum; 2009 Jun; 38(6):434-43. PubMed ID: 18538830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
